{
  "id": 488538,
  "title": "Why is Replimune stock surging today?",
  "url": "https://urgent.news/2026/08/10/why-is-replimune-stock-surging-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-10T17:35:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-replimune-stock-surging-today-93CH-4849987"
  },
  "original_language": "en",
  "account": null,
  "summary": "Replimune stock experienced a 15.3% surge today, reaching a new 52-week high of $13.99, as investors responded to a combination of factors. The catalysts included the company's fiscal Q4 2026 earnings release, the FDA's accelerated approval of TUDRIQEV, an engineered oncolytic virus, for use alongside Bristol Myers Squibb's nivolumab in treating advanced cutaneous melanoma, and a $150 million equity offering priced at $12.06 per share. Analyst sentiment had already turned bullish following the FDA decision, with BMO Capital raising its price target to $20 and Wedbush upgrading the stock to Outperform from Neutral. The broader market movements were relatively muted, with the S&P 500 essentially flat, the Dow Jones slightly down, and the Nasdaq slightly red, indicating that REPL's significant gain was driven by company-specific events.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}